Trials / Completed
CompletedNCT04938752
Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)
An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA 2811 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and DA-2811-R after a single oral dose in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-2811 | single dose administration (one tablet once a day) |
| DRUG | DA-2811-R | single dose administration (one tablet once a day) |
Timeline
- Start date
- 2021-07-08
- Primary completion
- 2021-08-20
- Completion
- 2021-08-20
- First posted
- 2021-06-24
- Last updated
- 2022-06-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04938752. Inclusion in this directory is not an endorsement.